References
- Norwood O T. Male pattern baldness: classification and incidence. South Med J 1975; 68: 1359–1365
- Whiting D A. Male pattern hair loss: current understanding. Int J Dermatol 1998; 37: 561–566
- Hans W. Male and female androgenetic alopecia. Evidence-based dermatology1st edn, H Williams, M Bigby, T Diepgen, A Herxheimer, L Naldi, B Rzany. Blackwell, London 2003; 571–576
- Gann P, Hennekens C, Ma J, Longcope C, Stampfer M. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996; 88: 1118–1122
- Vermeulen A, Verdonck L, Kaufman J M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666–3672
- Sawaya M E, Price V H. Different levels of 5alphareductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997; 109: 296–300
- Giltay E J, Toorians A W, Sarabdjitsingh A R, de Vries N A, Gooren L J. Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-to-male transsexuals. J Endocrinol 2004; 180: 107–112
- Parsons J K, Carter H B, Landis P. Higher serum free testosterone is associated with an increased risk of prostate cancer: results from the Baltimore Longitudinal Study on Aging. J Urol 2004; 171: 116–118
- Platz E A, Leitzmann M, Rifai N. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the PSA era. Cancer Epidemiol Biomarkers Prev 2005; 14: 1262–1269
- Roddam A W, Allen N E, Appleby P, Key T J. Endogenous hormones, prostate cancer collaborative group, endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170–183
- Gann P H, Hennekens C H, Ma J. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996; 88: 1118–1126
- Mohr B A, Feldman H A, Kalish L A, Longcope C, McKinlay J B. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology 2001; 57: 930–935
- Mearini L, Costantini E, Zucchi A, Mearini E, Bini V, Cottini E, Porena M. Testosterone levels in benign prostatic hypertrophy and prostate cancer. Urol Int 2008; 80: 134–140
- Olsen E A. Androgenetic alopecia. Disorders of hair growth – diagnosis and treatment, E A Olsen. McGraw-Hill, New York 1994; 257–283
- Ernest H, Rosalind A B, Barry I G. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey: short communication. Cancer Epidemiology, Biomarkers Prevent 2000; 9: 523–527
- Bong R O, Seong J K, Jaı D M, Hyeung N K, Dong D K, Young H W, Soo B R, Yang I P. Association of benign prostatic hyperplasia with male pattern baldness. Urology 1998; 51: 744–748
- WenChieh C, Chao-Chun Y, Guan-Yu C, Meng-Chie W, Hamm-Ming S, Tzong-Shin T. Patients with a large prostate show a higher prevalence of androgenetic alopecia. Arch Dermatol Res 2004; 296: 245–249
- Giles G G, Severi G, Sinclair R, English D R, McCredie M R, Johnson W, Boyle P, Hopper J L. Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. Cancer Epidemiol Biomarkers Prev 2002; 11: 549–553
- Wendy D W, Joellen M S, Denis T, Samuel M L, Lauren M, Pamela S, David F P, Cary N R, Anderson E E, Walther P J. Early onset baldness and prostate cancer risk. Cancer Epidemiol Biomarkers Prevent 2000; 9: 325–328
- Demark W W, Lesko S M, Conaway M R, Robertson C N, Clark R V, Lobaugh B, Mathias B J, Strigo T S, Paulson D F. Serum androgens: associations with prostate cancer risk and hair patterning. J Androl 1997; 18: 495–500